The emergence of Retatrutide ZPHC, at a concentration of 120mg, is sparking considerable excitement within the weight loss community. This novel dual GIP and GLP-1 agonist medication appears to provide notable improvements in body reduction compared to existing therapies. Early clinical data have indicated significant decreases in body mass , possi